{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:07:15Z","timestamp":1778274435432,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1038\/ncpgasthep0475","type":"journal-article","created":{"date-parts":[[2006,5,4]],"date-time":"2006-05-04T09:50:54Z","timestamp":1146736254000},"page":"290-293","source":"Crossref","is-referenced-by-count":7,"title":["Combined oral and topical mesalazine treatment for extensive ulcerative colitis"],"prefix":"10.1038","volume":"3","author":[{"given":"Alan C","family":"Moss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S","family":"Cheifetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Peppercorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpgasthep0475_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(02)07499-8","volume":"359","author":"RJ Farrell","year":"2002","unstructured":"Farrell RJ and Peppercorn MA (2002) Ulcerative colitis. Lancet 359: 331\u2013340","journal-title":"Lancet"},{"key":"BFncpgasthep0475_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/gut.52.2.159","volume":"52","author":"EM Alstead","year":"2003","unstructured":"Alstead EM and Nelson-Piercy C (2003) Inflammatory bowel disease in pregnancy. Gut 52: 159\u2013161","journal-title":"Gut"},{"key":"BFncpgasthep0475_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijgo.2005.06.003","volume":"90","author":"G Elbaz","year":"2005","unstructured":"Elbaz G  et al. (2005) Inflammatory bowel disease and preterm delivery. Int J Gynaecol Obstet 90: 193\u2013197","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 4","key":"BFncpgasthep0475_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1365-2036.2004.02056.x","volume":"20","author":"SP Travis","year":"2004","unstructured":"Travis SP (2004) Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 20 (Suppl 4): 88\u201392","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0475_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1046\/j.1365-2168.1999.01076.x","volume":"86","author":"KO Olsen","year":"1999","unstructured":"Olsen KO  et al. (1999) Fertility after ileal pouch\u2013anal anastomosis in women with ulcerative colitis. Br J Surg 86: 493\u2013495","journal-title":"Br J Surg"},{"key":"BFncpgasthep0475_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00404-003-0489-6","volume":"270","author":"S Ferrero","year":"2004","unstructured":"Ferrero S and Ragni N (2004) Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 270: 79\u201385","journal-title":"Arch Gynecol Obstet"},{"key":"BFncpgasthep0475_CR7","first-page":"1188","volume":"88","author":"S Hanauer","year":"1993","unstructured":"Hanauer S  et al. (1993) Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 88: 1188\u20131197","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0475_CR8","first-page":"229","volume":"2","author":"M Miglioli","year":"1990","unstructured":"Miglioli M  et al. (1990) Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. Eur J Gastroenterol Hepatol 2: 229\u2013234","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFncpgasthep0475_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1136\/gut.29.5.669","volume":"29","author":"SA Riley","year":"1988","unstructured":"Riley SA  et al. (1988) Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 29: 669\u2013674","journal-title":"Gut"},{"key":"BFncpgasthep0475_CR10","doi-asserted-by":"crossref","unstructured":"Schroeder KW  et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625\u20131629","DOI":"10.1056\/NEJM198712243172603"},{"key":"BFncpgasthep0475_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7326\/0003-4819-115-5-350","volume":"115","author":"CA Sninsky","year":"1991","unstructured":"Sninsky CA  et al. (1991) Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 115: 350\u2013355","journal-title":"Ann Intern Med"},{"key":"BFncpgasthep0475_CR12","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/j.1572-0241.2005.00248.x","volume":"100","author":"SB Hanauer","year":"2005","unstructured":"Hanauer SB  et al. (2005) Delayed-release oral mesalamine at 4.8 g\/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II Trial. Am J Gastroenterol 100: 2478\u20132485","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0475_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1023\/A:1017987229718","volume":"47","author":"JP Gisbert","year":"2002","unstructured":"Gisbert JP  et al. (2002) Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 47: 471\u2013488","journal-title":"Dig Dis Sci"},{"key":"BFncpgasthep0475_CR14","doi-asserted-by":"crossref","unstructured":"Sutherland L and MacDonald JK (2003) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. The Cochrane Database of Systematic Reviews, Issue 3, Art. No CD000543","DOI":"10.1002\/14651858.CD000543"},{"key":"BFncpgasthep0475_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1053\/jcgh.2003.50006","volume":"1","author":"W Kruis","year":"2003","unstructured":"Kruis W  et al. (2003) The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 1: 36\u201343","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFncpgasthep0475_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3109\/00365529008997590","volume":"25","author":"M Campieri","year":"1990","unstructured":"Campieri M  et al. (1990) Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 25: 663\u2013668","journal-title":"Scand J Gastroenterol"},{"key":"BFncpgasthep0475_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/gut.32.8.929","volume":"32","author":"M Campieri","year":"1991","unstructured":"Campieri M  et al. (1991) Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 32: 929\u2013931","journal-title":"Gut"},{"key":"BFncpgasthep0475_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00054725-199805000-00001","volume":"4","author":"SB Hanauer","year":"1998","unstructured":"Hanauer SB  et al. (1998) Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The US PENTASA Enema Study Group. Inflamm Bowel Dis 4: 79\u201383","journal-title":"Inflamm Bowel Dis"},{"key":"BFncpgasthep0475_CR19","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","volume":"95","author":"RD Cohen","year":"2000","unstructured":"Cohen RD  et al. (2000) A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95: 1263\u20131276","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0475_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1046\/j.1365-2036.1999.00642.x","volume":"13","author":"G Frieri","year":"1999","unstructured":"Frieri G  et al. (1999) Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 13: 1413\u20131417","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0475_CR21","first-page":"1867","volume":"92","author":"M Safdi","year":"1997","unstructured":"Safdi M  et al. (1997) A double blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92: 1867\u20131871","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0475_CR22","first-page":"1143","volume":"92","author":"G D'Albasio","year":"1997","unstructured":"D'Albasio G  et al. (1997) Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double blind study. Am J Gastroenterol 92: 1143\u20131147","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0475_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1080\/00365520310008133","volume":"39","author":"LP Piodi","year":"2004","unstructured":"Piodi LP  et al. (2004) Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 39: 154\u2013157","journal-title":"Scand J Gastroenterol"},{"key":"BFncpgasthep0475_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S1590-8658(02)80072-X","volume":"34","author":"P Paoluzi","year":"2002","unstructured":"Paoluzi P  et al. (2002) Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild\u2013moderate relapse of ulcerative colitis: one-year randomised multicenter trial. Dig Liver Dis 34: 787\u2013793","journal-title":"Dig Liver Dis"},{"key":"BFncpgasthep0475_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-2036.2001.00913.x","volume":"15","author":"M Vecchi","year":"2001","unstructured":"Vecchi M  et al. (2001) Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 15: 251\u2013256","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0475_CR26","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/gut.2004.060103","volume":"54","author":"P Marteau","year":"2005","unstructured":"Marteau P  et al. (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54: 960\u2013965","journal-title":"Gut"}],"container-title":["Nature Clinical Practice Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0475","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:02:49Z","timestamp":1684440169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["BFncpgasthep0475"],"URL":"https:\/\/doi.org\/10.1038\/ncpgasthep0475","relation":{},"ISSN":["1743-4378","1743-4386"],"issn-type":[{"value":"1743-4378","type":"print"},{"value":"1743-4386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}